Literature DB >> 17504162

Labeling biomolecules with radiorhenium: a review of the bifunctional chelators.

Guozheng Liu1, Donald J Hnatowich.   

Abstract

For radiotherapy, biomolecules such as intact antibodies, antibody fragments, peptides, DNAs and other oligomers have all been labeled with radiorhenium ((186)Re and (188)Re). Three different approaches have been employed that may be referred to as direct, indirect and integral labeling. Direct labeling applies to proteins and involves the initial reduction of endogenous disulfide bridges to provide chelation sites. Indirect labeling can apply to most biomolecules and involves the initial attachment of an exogenous chelator. Finally, integral labeling is a special case applying only to small molecules in which the metallic radionuclide serves to link two parts of a biomolecule together in forming the labeled complex. While the number of varieties for the direct and integral radiolabeling approaches is rather limited, a fairly large and diverse number of chelators have been reported in the case of indirect labeling. Our objective herein is to provide an overview of the various chelators that have been used in the indirect labeling of biomolecules with radiorhenium, including details on the labeling procedures, the stability of the radiolabel and, where possible, the influence of the label on biological properties.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17504162      PMCID: PMC1949414          DOI: 10.2174/187152007780618144

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  103 in total

1.  Imaging of apoptosis (programmed cell death) with 99mTc annexin V.

Authors:  F G Blankenberg; P D Katsikis; J F Tait; R E Davis; L Naumovski; K Ohtsuki; S Kopiwoda; M J Abrams; H W Strauss
Journal:  J Nucl Med       Date:  1999-01       Impact factor: 10.057

2.  186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.

Authors:  C E Kotts; F M Su; C Leddy; T Dodd; S Scates; M R Shalaby; C M Wirth; D Giltinan; R W Schroff; A R Fritzberg; H M Shepard; D J Slamon; B M Hutchins
Journal:  Cancer Biother Radiopharm       Date:  1996-04       Impact factor: 3.099

Review 3.  Towards new transition metal-based hypoxic selective agents for therapy and imaging.

Authors:  P J Blower; J R Dilworth; R I Maurer; G D Mullen; C A Reynolds; Y Zheng
Journal:  J Inorg Biochem       Date:  2001-05       Impact factor: 4.155

4.  188Re-ethylene dicysteine: a novel agent for possible use in endovascular radiation therapy.

Authors:  T Das; S Banerjee; G Samuel; H D Sarma; N Ramamoorthy; M R Pillai
Journal:  Nucl Med Commun       Date:  2000-10       Impact factor: 1.690

5.  Organometallic 99mTc-aquaion labels peptide to an unprecedented high specific activity.

Authors:  A Egli; R Alberto; L Tannahill; R Schibli; U Abram; A Schaffland; R Waibel; D Tourwé; L Jeannin; K Iterbeke; P A Schubiger
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

Review 6.  New directions in the coordination chemistry of 99mTc: a reflection on technetium core structures and a strategy for new chelate design.

Authors:  Sangeeta Ray Banerjee; Kevin P Maresca; Lynn Francesconi; John Valliant; John W Babich; Jon Zubieta
Journal:  Nucl Med Biol       Date:  2005-01       Impact factor: 2.408

7.  Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent.

Authors:  A R Fritzberg; P G Abrams; P L Beaumier; S Kasina; A C Morgan; T N Rao; J M Reno; J A Sanderson; A Srinivasan; D S Wilbur
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

Review 8.  Search for new and improved radiolabeling methods for monoclonal antibodies. A review of different methods.

Authors:  J V Hiltunen
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

9.  Technetium-99m labelled hydrazinonicotinamido human non-specific polyclonal immunoglobulin G for detection of infectious foci: a comparison with two other technetium-labelled immunoglobulin preparations.

Authors:  R A Claessens; O C Boerman; E B Koenders; W J Oyen; J W van der Meer; F H Corstens
Journal:  Eur J Nucl Med       Date:  1996-04

10.  Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice.

Authors:  S Kinuya; K Yokoyama; H Tega; T Hiramatsu; S Konishi; W Yamamoto; N Shuke; T Aburano; N Watanabe; T Takayama; T Michigishi; N Tonami
Journal:  Jpn J Cancer Res       Date:  1998-08
View more
  11 in total

1.  Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions.

Authors:  Valerie Carroll; Dustin W Demoin; Timothy J Hoffman; Silvia S Jurisson
Journal:  Radiochim Acta       Date:  2012-08       Impact factor: 1.440

Review 2.  Bifunctional chelators for radiorhenium: past, present and future outlook.

Authors:  Diana R Melis; Andrew R Burgoyne; Maarten Ooms; Gilles Gasser
Journal:  RSC Med Chem       Date:  2022-01-14

3.  Monooxorhenium(V) complexes with 222-N2S2 MAMA ligands for bifunctional chelator agents: Syntheses and preliminary in vivo evaluation.

Authors:  Dustin Wayne Demoin; Ashley N Dame; William D Minard; Fabio Gallazzi; Gary L Seickman; Tammy L Rold; Nicole Bernskoetter; Michael E Fassbender; Timothy J Hoffman; Carol A Deakyne; Silvia S Jurisson
Journal:  Nucl Med Biol       Date:  2016-08-31       Impact factor: 2.408

4.  (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.

Authors:  Anna Orlova; Thuy A Tran; Torun Ekblad; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-22       Impact factor: 9.236

Review 5.  Perspectives on metals-based radioimmunotherapy (RIT): moving forward.

Authors:  Jordan M White; Freddy E Escorcia; Nerissa T Viola
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

6.  Comparison of two peptide radiotracers for prostate carcinoma targeting.

Authors:  Bluma Linkowski Faintuch; Erica A Oliveira; Eutimio G F Nunez; Ana M Moro; P K Nanda; Charles J Smith
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 7.  Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy.

Authors:  Licia Uccelli; Petra Martini; Micol Pasquali; Alessandra Boschi
Journal:  Biomed Res Int       Date:  2017-08-30       Impact factor: 3.411

Review 8.  188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy.

Authors:  Alessandra Boschi; Petra Martini; Licia Uccelli
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-19

9.  Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design.

Authors:  Liang Zhang; Sumit Bhatnagar; Emily Deschenes; Greg M Thurber
Journal:  Sci Rep       Date:  2016-05-05       Impact factor: 4.379

10.  Design and Synthesis of 99mTcN-Labeled Dextran-Mannose Derivatives for Sentinel Lymph Node Detection.

Authors:  Alessandra Boschi; Micòl Pasquali; Claudio Trapella; Alessandro Massi; Petra Martini; Adriano Duatti; Remo Guerrini; Vinicio Zanirato; Anna Fantinati; Erika Marzola; Melchiore Giganti; Licia Uccelli
Journal:  Pharmaceuticals (Basel)       Date:  2018-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.